...
首页> 外文期刊>Gynecologic Oncology: An International Journal >Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenter retrospective study (CTF Study)
【24h】

Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenter retrospective study (CTF Study)

机译:意大利多中心回顾性研究(CTF研究)表明,对于新辅助化疗和根治性子宫切除术治疗的Ib2-IIb期宫颈癌患者,手术样本的病理反应是独立的预后变量

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives The purpose of this retrospective multicenter study was to correlate patterns of recurrences and clinical outcome of cervical cancer patients who underwent neoadjuvant chemotherapy [NACT] to surgery. Methods This study was conducted on 333 patients with FIGO stage Ib2-IIb cervical cancer who underwent NACT to surgery with pelvic lymphadenectomy. The median follow-up was 66.5 months (range, 8-212 months). Overall optimal response rate was the sum of complete and optimal partial response rates. Results An overall optimal response was obtained in 64 patients (19.2%). As for the 220 sub-optimal responders (66.1%), 127 patients had negative nodes and negative parametria and/or surgical margins, 75 patients had positive nodes with positive or negative parametria and/or surgical margins, and 18 patients had positive parametria and/or surgical margins with negative nodes. At the time of the present analysis, 79 (23.7%) of the 333 patients had a recurrence after a median time of 14.9 months (range, 4.5-123 months). Recurrent disease was pelvic in 50 (63.3%), extra-pelvic in 22 (27.9%), and both in 7 (8.8%). On multivariate analysis, pathological response to NACT was an independent prognostic variable for recurrence-free and overall survival. Patients who did not achieve an overall optimal response had a 2.757-fold higher risk of recurrence and a 5.413-fold higher risk of death than those who obtained an overall optimal response. Conclusions Results appear to suggest that the chemo-surgical approach is an effective therapeutic option for patients with stage Ib2-IIb cervical cancer and that pathological response to NACT is the strongest prognostic factor for the outcome.
机译:目的这项回顾性多中心研究的目的是将接受新辅助化疗[NACT]的宫颈癌患者的手术复发模式与临床结局联系起来。方法本研究针对333例FIGO Ib2-IIb宫颈癌患者行NACT盆腔淋巴结清扫术。中位随访时间为66.5个月(范围8-212个月)。总体最佳响应率是完全和最佳部分响应率的总和。结果64例患者获得了总体最佳缓解(19.2%)。至于220例次优反应者(66.1%),有127例淋巴结阴性,副参数和/或手术切缘阴性,有75例淋巴结阳性,副参数和/或手术切缘阳性或阴性,有18例副参数阳性和/或具有阴性淋巴结的手术切缘。在目前的分析时,333例患者中有79例(23.7%)在中位时间为14.9个月(范围4.5-123个月)后复发。复发性疾病的盆腔占50(63.3%),盆腔外占22(27.9%),两者均占7(8.8%)。在多变量分析中,对NACT的病理反应是无复发和总体生存的独立预后变量。与获得总体最佳应答的患者相比,未获得总体最佳应答的患者复发风险高2.757倍,死亡风险则高5.413倍。结论结果似乎表明,化学外科手术方法是Ib2-IIb期宫颈癌患者的有效治疗选择,对NACT的病理反应是预后的最强因素。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号